Establishing a model composed of immune-related gene-modules to predict tumor immunotherapy response-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Establishing a model composed of immune-related gene-modules to predict tumor immunotherapy response

Published:2024-07-18 Issue:1 Volume:14 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Fu Deqiang,Weng Xiaoyuan,Su Yunxia,Hong Binhuang,zhao Aiyue,Lin Jianqing

Funder

Natural Science Foundation of Fujian Province

The Second Affiliated Hospital of Fujian Medical University

Quanzhou City Science and Technology Program

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41598-024-67742-y.pdf

Reference56 articles.

1. Robert, C. et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 384, 1109–1117. https://doi.org/10.1016/s0140-6736(14)60958-2 (2014).

2. Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028. https://doi.org/10.1056/NEJMoa1501824 (2015).

3. Zhu, A. X. et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol. 19, 940–952. https://doi.org/10.1016/s1470-2045(18)30351-6 (2018).

4. Fuchs, C. S. et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 4, e180013. https://doi.org/10.1001/jamaoncol.2018.0013 (2018).

5. Kucukgoz Gulec, U. et al. Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer. Archiv. Gynecol. Obstet. 300, 377–382. https://doi.org/10.1007/s00404-019-05180-2 (2019).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3